trial · primary record
Anlotinib Hydrochloride Capsules
Nasopharyngeal Cancinoma (NPC)
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 214 |
| Primary completion | 2033-12-31 |
| Primary endpoint | Post-induction Therapy Complete Response Rate (post-IT CRR) |
| Registry ID | NCT07904819 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:33:34.968Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07904819
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.